Previous 10 | Next 10 |
Two new Breakout Stocks for Week 21 with better than 10% short-term upside potential, and two Dow 30 Picks. Average cumulative returns now up to +67.1% YTD. High frequency breakouts continue despite Negative Momentum Gauge® signals, with peak gains in 1 of 4 picks above 10%: SCSC...
The following slide deck was published by Mirum Pharmaceuticals, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Mirum Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation
Mirum Pharmaceuticals press release (NASDAQ:MIRM): Q1 GAAP EPS of -$1.17 beats by $0.23. Revenue of $12.89M beats by $4.43M. As of March 31, 2022, Mirum had cash, cash equivalents, restricted cash equivalents, and investments of $239.9 million. For further details see: Mirum Pharmaceuti...
- Total revenue for the first quarter of 2022 was $12.9 million including net product revenue for LIVMARLI ® (maralixibat) oral solution of $10.9 million. - Conference call to provide business updates today, May 5 at 5:30 a.m. PT/8:30 a.m. ET Mirum Pharmaceuticals, ...
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter financial results on Thursday, May 5, 2022. That same day, Mirum will host a conference call to discuss the company’s progress and priorities for 2022. Conference call details: Thur...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Value has outperformed growth by a substantial margin ove...
RemeGen, a Yantai biotech with a deep portfolio of antibody and dual therapies, completed a $410 million IPO on the Shanghai Star Exchange. Nanjing Biosion out-licensed global rights (ex-China) to Pyxis Oncology for an immunotherapy aimed at solid tumor cancers in a $226 million agree...
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2021 Earnings Conference Call March 9, 2022 16:30 ET Corporate Participants Ian Clements - Chief Financial Officer Chris Peetz - President, Chief Executive Officer Peter Radovich - Chief Operating Officer Pamela Vig - Chief Scientific Officer Ian Clements...
Mirum Pharmaceuticals press release (NASDAQ:MIRM): Q4 net income of $57.5M Revenue of $3.14M. For further details see: Mirum Pharmaceuticals reports Q4 results
- Strong commercial launch underway with LIVMARLI ® (maralixibat) oral solution; net product revenue of $3.1 million for the first quarter of launch, total 2021 company revenue of $19.1 million - Expect at least $8.0 million in LIVMARLI net product sales in first quarter 20...
News, Short Squeeze, Breakout and More Instantly...
Mirum Pharmaceuticals Inc. Company Name:
MIRM Stock Symbol:
NASDAQ Market:
Mirum Pharmaceuticals Inc. Website:
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report second quarter 2024 financial results on August 7, 2024. Mirum will also host a conference call to discuss the second quarter 2024 financial results and recent corporate progress. Conference call details: Wednesd...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC)...
European Commission grants LIVMARLI marketing authorization for treatment of PFIC in patients three months and older. Approval follows positive opinion from CHMP concluding LIVMARLI’s clinical benefit over existing therapy in PFIC. LIVMARLI also received positive COMP opinion recom...